Taking all quality controls into account, our results indicated that only antibody FSHR323 proved suitable for target validation of FSHR in an immunohistochemical setting for cancer, inciting us to think that only the IHC results from the previous studies using this particular antibody are to be trusted. This evidence concerns the gene FSHR and cancer.